Rankings
▼
Calendar
▼
LBRX Q2 2024 Earnings Report — LB Pharmaceuticals Inc Common Stock Revenue & Financial Results | Market Cap Arena
LB Pharmaceuticals Inc Common Stock
LBRX
Q2 2024 Earnings
Reported June 30, 2024
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q2 2024
Q1 2024
Q2 2023
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$27M
-$17M
—
-59.9%
—
EPS (Diluted)
$-7.82
$-4.56
—
-71.5%
—
Free Cash Flow
-$16M
-$10M
—
-64.4%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$24M
Selling & Marketing
$0
General & Administrative
$2M
SG&A Expenses
$2M
Other Expenses
$0
Operating Expenses
$27M
Cost & Expenses
$27M
OPERATING INCOME
-$27M
Interest Income
$411.0K
Interest Expense
$0
Other Income/Expenses
-$1M
INCOME BEFORE TAX
-$28M
Income Tax Expense
$0
Net Income from Continuing Ops
-$28M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$28M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$28M
D&A
$3.0K
EBIT
-$27M
EBITDA
-$27M
EPS
-$8
EPS Diluted
-$8
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$28M
Depreciation & Amortization
$3.0K
Stock-Based Compensation
$339.0K
Deferred Income Tax
$0
Other Non-Cash Items
$2M
Change in Working Capital
$10M
OPERATING CASH FLOW
-$16M
Capital Expenditure
-$41.0K
Acquisitions (Net)
$0
Purchases of Investments
-$4M
Sales/Maturities of Investments
$0
Other Investing Activities
$11M
NET CASH FROM INVESTING
$7M
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$3.0K
NET CASH FROM FINANCING
$3.0K
FREE CASH FLOW
-$16M
Net Change in Cash
-$9M
marketcaparena.com
← FY 2024
LBRX Overview
Q3 2024 →